2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis.

摘要: Abstract Objectives To update the recommendations on prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by French National Authority for Health (HAS). This was performed under aegis Bone Section Society Rheumatology (SFR) Osteoporosis Research Information Group (GRIO), collaboration with four learned societies (primary-care, gastroenterology, internal medicine, nephrology). Methods A task force composed members medical specialties involved managing patients conducted a systematic literature review according to method developed HAS then used results develop updated recommendations. Results These are intended all physicians management who scheduled start, or taking, long-term glucocorticoid therapy (≥ 3 months) any dose reason. In postmenopausal women men older than 50 years age, is warranted presence following risk factors fracture: history bone frailty fracture after mineral density T-score ≤ −2.5 at one more sites, age ≥ 70 years, dosage ≥ 7.5 mg/d prednisone-equivalent longer 3 months. Bisphosphonates can be these situations; teriparatide given as first-line high but reimbursed statutory health insurance system only having two prevalent vertebral fractures. The lower nonmenopausal younger whom decisions should rest case-by-case evaluation. Conclusion clarify pharmacological osteoporosis.